1. Sanguinetti CM. N-acetylcysteine in COPD: why, how, and when?. Multidiscip Respir Med. 2016;11:8. Published 2016 Feb 3. doi:10.1186/s40248-016-0039-2
2. Tian H, Zhou Y, Tang L, Wu F, Deng Z, Lin B, Huang P, Wei S, Zhao D, Zheng J, Zhong N, Ran P. High-dose N-acetylcysteine for long-term, regular treatment of early-stage chronic obstructive pulmonary disease (GOLD I-II): study protocol for a multicenter, double-blinded, parallel-group, randomized controlled trial in China. Trials. 2020 Sep 11;21(1):780. doi: 10.1186/s13063-020-04701-8.
3. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2020. https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf
4. Johnson K, McEvoy CE, Naqvi S, Wendt C, Reilkoff RA, Kunisaki KM, Wetherbee EE, Nelson D, Tirouvanziam R, Niewoehner DE. High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis. 2016 Apr 21;11:799-807. doi: 10.2147/COPD.S102375.
5. Ansari SF, Memon M, Brohi N, Tahir A. N-acetylcysteine in the Management of Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Cureus. 2019 Nov 5;11(11):e6073. doi: 10.7759/cureus.6073.
6. Calverley P, Rogliani P, Papi A. Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review. Drug Saf. 2021 Mar;44(3):273-290. doi: 10.1007/s40264-020-01026-y. Epub 2020 Dec 16. PMID: 33326056; PMCID: PMC7892733.